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Abstract
Mutations in the Plasmodium falciparum ‘chloroquine resistance transporter’ (PfCRT) confer
resistance to chloroquine (CQ) and related antimalarials by enabling the protein to transport
these drugs away from their targets within the parasite’s digestive vacuole (DV). However,
CQ resistance-conferring isoforms of PfCRT (PfCRTCQR) also render the parasite hypersen-
sitive to a subset of structurally-diverse pharmacons. Moreover, mutations in PfCRTCQR that
suppress the parasite’s hypersensitivity to these molecules simultaneously reinstate its sen-
sitivity to CQ and related drugs. We sought to understand these phenomena by characteriz-
ing the functions of PfCRTCQR isoforms that cause the parasite to become hypersensitive to
the antimalarial quinine or the antiviral amantadine. We achieved this by measuring the abili-
ties of these proteins to transport CQ, quinine, and amantadine when expressed in Xenopus
oocytes and complemented this work with assays that detect the drug transport activity of
PfCRT in its native environment within the parasite. Here we describe twomechanistic expla-
nations for PfCRT-induced drug hypersensitivity. First, we show that quinine, which normally
accumulates inside the DV and therewithin exerts its antimalarial effect, binds extremely
tightly to the substrate-binding site of certain isoforms of PfCRTCQR. By doing so it likely
blocks the normal physiological function of the protein, which is essential for the parasite’s
survival, and the drug thereby gains an additional killing effect. In the second scenario, we
show that although amantadine also sequesters within the DV, the parasite’s hypersensitivity
to this drug arises from the PfCRTCQR-mediated transport of amantadine from the DV into
the cytosol, where it can better access its antimalarial target. In both cases, the mutations
that suppress hypersensitivity also abrogate the ability of PfCRTCQR to transport CQ, thus
explaining why rescue from hypersensitivity restores the parasite’s sensitivity to this antima-
larial. These insights provide a foundation for understanding clinically-relevant observations
of inverse drug susceptibilities in the malaria parasite.
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Author Summary
In acquiring resistance to one drug, many pathogens and cancer cells become hypersensi-
tive to other drugs. This phenomenon could be exploited to combat existing drug resis-
tance and to delay the emergence of resistance to new drugs. However, much remains to
be understood about the mechanisms that underlie drug hypersensitivity in otherwise
drug-resistant microbes. Here, we describe two mechanisms by which the Plasmodium fal-
ciparum ‘chloroquine resistance transporter’ (PfCRT) causes the malaria parasite to
become hypersensitive to structurally-diverse drugs. First, we show that an antimalarial
drug that normally exerts its killing effect within the parasite’s digestive vacuole is also
able to bind extremely tightly to certain forms of PfCRT. This activity will block the natu-
ral, essential function of the protein and thereby provide the drug with an additional kill-
ing effect. The second mechanism arises when a cytosolic-acting drug that normally
sequesters within the digestive vacuole is leaked back into the cytosol via PfCRT. In both
cases, mutations that suppress hypersensitivity also abrogate the ability of PfCRT to trans-
port chloroquine, thus explaining why rescue from hypersensitivity restores the parasite’s
sensitivity to this antimalarial. These insights provide a foundation for understanding and
exploiting the hypersensitivity of chloroquine-resistant parasites to several of the current
antimalarials.
Introduction
Originally identified as the protein responsible for conferring resistance to the ‘wonder-drug’
chloroquine (CQ) [1, 2], the Plasmodium falciparum ‘chloroquine resistance transporter’
(PfCRT) has become a key player in the malaria parasite’s steadily expanding resistance to
drugs [3–5]. The isoforms of PfCRT that confer CQ resistance (PfCRTCQR) render the parasite
less susceptible to many other compounds [6–10], but also simultaneously induce hypersensi-
tivity to a subset of structurally-diverse molecules [6, 10–18]. This phenomenon, whereby resis-
tance to one drug causes hypersensitivity to another, is known as ‘inverse susceptibility’ or
‘collateral sensitivity’ and has been observed in a wide range of pathogens and cancer cells [19–
22]. The growing awareness of the propensity of drug-resistant pathogens to exhibit hypersen-
sitivity to one or more other drugs has sparked interest in the potential for exploiting this
Achilles’ heel to combat existing drug resistance and to delay the emergence of resistance to
new drugs [19]. However, it is not known how PfCRTCQR isoforms induce hypersensitivity to
certain drugs and, more generally, much remains to be understood about the molecular mecha-
nisms that underpin collateral sensitivity in pathogens and cancer cells [20–22].
The ability of PfCRT to affect the activity of so many compounds is likely to be a product of
its location at the membrane of the parasite’s digestive vacuole (DV) [1, 11]; an acidic compart-
ment in which many types of antimalarials accumulate and/or act. The parasite takes up hemo-
globin and digests it within this compartment in order to grow within its host erythrocyte. This
process releases heme monomers that are detoxified via conversion into the inert crystal hemo-
zoin. Quinoline-type antimalarial drugs, including CQ, quinine, and quinidine, concentrate
within the DV via ‘weak-base trapping’ [23], where they exert an antimalarial effect by binding
to heme and arresting its detoxification [24–27]. Resistance to these quinolines is associated
with reductions in the accumulation of the drugs within the DV [8, 11, 28] and we have previ-
ously obtained direct evidence of this phenomenon being due, at least in part, to the ability of
PfCRTCQR isoforms to efflux CQ, quinine, and quinidine from this compartment. This was
achieved by expressing a PfCRTCQR isoform from Dd2 parasites (PfCRTDd2) and the wild-type
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protein (PfCRT3D7) in Xenopus laevis oocytes. PfCRTDd2 was found to possess significant CQ,
quinine, and quinidine transport activity, whereas PfCRT3D7 did not [29–31]. These findings
were consistent with a number of biochemical studies that had provided indirect evidence of
drug transport via PfCRTCQR isoforms. For example, PfCRTCQR isoforms had been linked to
the efflux of CQ and quinine from parasite-infected red blood cells [32, 33], and PfCRTCQR
was also implicated in the quinoline-induced efflux of protons from the DV of CQ-resistant
parasites [34–36]. Moreover, the expression of PfCRTDd2 at endosomal membranes within Dic-
tyostelium discoideum reduced the accumulation of CQ and quinine within these vesicles, con-
sistent with the mutant protein mediating the transport of these two drugs [37, 38]. Aside from
modulating the parasite’s susceptibility to diverse pharmacons, PfCRT fulfills an essential [39,
40] but currently unresolved physiological function in the parasite.
In this study, we investigated the mechanistic basis of PfCRT-induced drug hypersensitivity
by characterizing the isoforms of PfCRT carried by nine different parasite lines (Table 1). These
lines were generated by Cooper, Johnson, and colleagues [11, 12, 14, 15] and were produced by
applying CQ, quinine, and/or amantadine pressure to either the CQ-sensitive strain 106/1 or
the CQ-resistant strain K1. CQ-resistant strains, including K1, are hypersensitive to amantadine
[13, 15]—a weak-base antiviral drug that is thought to accumulate in acidic organelles [41]. Like
all PfCRTCQR isoforms identified to date, the K1 variant of PfCRT (PfCRTK1) contains a muta-
tion at position 76, where a positively-charged lysine (K) residue is replaced by an uncharged
residue (usually threonine; T) (S1 Fig). The K76T mutation is necessary (but not sufficient) to
enable PfCRT to mediate the transport of protonated CQ [30, 42]. The version of PfCRT carried
by 106/1 retains 76K but is otherwise identical to PfCRTK1. Pressuring 106/1 parasites with
CQ resulted in the CQ-resistant lines 106/176T, 106/176I, and 106/176N, which carried either
PfCRTK1 or PfCRTK1 with an isoleucine (I) or an asparagine (N) at position 76 (76I-PfCRTK1
and 76N-PfCRTK1, respectively) [11]. The latter two lines displayed unexpected drug responses:
106/176I was hypersensitive to quinine and 106/176N was sensitive to quinidine [11, 12]. The
subsequent selection of 106/176I parasites with quinine resulted in the reintroduction of a posi-
tively-charged residue (C72R, Q352K, or Q352R) into 76I-PfCRTK1 that suppressed the para-
site’s hypersensitivity to quinine but also re-sensitized it to CQ [12]. This ‘reciprocal collateral
sensitivity’ was also observed when K1 parasites or the 106/176I line were pressured with aman-
tadine [14, 15]; the resulting parasites gained mutations in PfCRT (including S163R and
V369F), were no longer hypersensitive to amantadine, but were rendered sensitive to CQ.
We compared the abilities of these PfCRTK1 variants to transport CQ, quinine, quinidine,
and amantadine when expressed in Xenopus oocytes and complemented the amantadine work
with assays that detected the PfCRT-mediated transport of the drug in the parasite. Our find-
ings indicate that the hypersensitivity of the 106/176I line to quinine arises from the drug
exerting two antiplasmodial effects—its normal anti-hemozoin activity as well as potent inhibi-
tion of PfCRTCQR, which likely kills the parasite by blocking the normal function of the trans-
porter. By contrast, the hypersensitivity of CQ-resistant parasites to amantadine is due to its
PfCRTCQR-mediated efflux from the DV into the cytosol, where it appears to gain better access
to its antiplasmodial target. In both cases, the mutations that suppress hypersensitivity cause a
substantial or complete reduction in the capacity of PfCRTCQR for CQ transport, thus explain-
ing why rescue from hypersensitivity reinstates the parasite’s sensitivity to CQ.
Results
Expression of PfCRTK1 isoforms at the oocyte plasma membrane
We used a previously-described version of the PfCRTK1 coding sequence [42] to generate the
isoforms of pfcrt carried by the 106/1 and K1 parasite lines (Table 1). This version of the pfcrt
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sequence has been codon-harmonized for expression in Xenopus oocytes and encodes a reten-
tion motif-free form of PfCRT that expresses in a functional form at the oocyte plasma mem-
brane [42]. We conducted immunofluorescence assays (Fig 1A) to confirm the localization of
each of the PfCRTK1 variants to the oocyte plasma membrane and used a semiquantitative
western blot analysis [42] to establish that they were present at comparable levels in the oocyte
membrane (Fig 1B). Hence, any differences in drug transport activity between these isoforms
of PfCRT can be attributed to differences in their transport properties rather than differences
in expression.
Quinoline transport via PfCRT largely correlates with quinoline
resistance
To understand the mechanisms underlying the inverse drug susceptibilities of the 106/1- and
K1-derived lines, we characterized the transport properties of the respective PfCRTK1 variants
in Xenopus oocytes. A key advantage of the oocyte system is that it allows the transport activity
of PfCRT to be studied directly and in isolation, without confounding effects such as the bind-
ing of drugs to heme or interactions of the compound with other parasite targets or transport-
ers. The direction of [3H]drug transport in this system is from the acidic extracellular medium
(pH 5.0–6.0) into the oocyte cytosol (pH 7.1–7.2 [30]), which corresponds to the efflux of pro-
tonated drug from the acidic DV (pH 5.0–5.5 [43, 44]) into the parasite cytosol (pH 7.3 [45]).
Noninjected oocytes take up [3H]CQ, [3H]quinine, and [3H]quinidine to low levels via simple
diffusion of the neutral species of the drug (Fig 2A–2C); this represents the background level of
[3H]drug accumulation [29, 30]. We found that none of the PfCRTK1 isoforms carried by CQ-
sensitive exhibited CQ transport activity when expressed in oocytes (Fig 2A). By contrast, the
Table 1. The origins, drug susceptibilities, and PfCRT haplotypes of different 106/1 and K1 P. falciparum lines.
Line or
isolatea
Origin or
drug
selection
PfCRT variant Drug susceptibilityb (In vitro
resistance index)
Amino acid changes in PfCRTc
CQ QN QD 72 74 75 76 163 220 271 326 352 369 356 371
HON Africa PfCRT3D7 1 1 1 C M N K S A Q N Q V I R
Dd2 Indochina/
Laos
PfCRTDd2 11.78 ± 0.18 1.82 ± 0.31 2.88 ± 0.46 C I E T S S E S Q V T I
106/1 Sudan 76K-PfCRTK1 1.10 ± 0.06 1.08 ± 0.06 1.01 ± 0.01 C I E K S S E S Q V I I
106/176T CQ PfCRTK1 12.95 ± 0.95 1.69 ± 0.19 1.95 ± 0.05 C I E T S S E S Q V I I
106/176N CQ 76N-PfCRTK1 8.60 ± 0.90 1.56 ± 0.16 1.08 ± 0.08 C I E N S S E S Q V I I
106/176I CQ 76I-PfCRTK1 15.66 ± 2.20 0.11 ± 0.04 1.72 ± 0.13 C I E I S S E S Q V I I
106/172R,76I CQ then QN 72R,76I-PfCRTK1 1.13 ± 0.07 0.76 ± 0.07 0.87 ± 0.06 R I E I S S E S Q V I I
106/176I,352K CQ then QN 76I,352K-PfCRTK1 0.91 ± 0.09 0.93 ± 0.25 1.28 ± 0.07 C I E I S S E S K V I I
106/176I,352R CQ then QN 76I,352R-PfCRTK1 1.58 ± 0.02 0.99 ± 0.16 0.88 ± 0.02 C I E I S S E S R V I I
106/176I,369F CQ then
AMTd
76I,369F-PfCRTK1 3.53 0.28 0.98 C I E I S S E S Q F I I
K1AM CQ then
AMT
163R,356V-PfCRTK1 0.95 0.72 n.d. C I E T R S E S Q V V I
aThe 106/1-derived lines were generated by Cooper and colleagues [11, 12, 14] and the K1AM line was produced by Johnson et al. [15].
bThe susceptibilities of the parasite lines to CQ, quinine (QN), and quinidine (QD) were collated from Cooper et al. [11, 12, 14] and Johnson et al. [15]. The
drug resistance index is the IC50 for a drug in a given strain or line divided by the IC50 determined in the same study in a drug-sensitive reference strain (i.e.,
106/1, HON, or GC03). The indices were calculated from a single study or are the mean of values from two (± range/2) or  three (± SEM) studies.
cResidues that differ from the wild-type amino acid sequence (e.g., the PfCRT sequence carried by 3D7, D10, and HON parasites) are shown in bold italics.
dCQ-resistant parasites are hypersensitive to amantadine [13, 15].
doi:10.1371/journal.ppat.1005725.t001
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expression of PfCRTK1 variants from CQ-resistant parasites caused significant increases in the
accumulation of CQ. Indeed, we observed a positive correlation between the ability of a
PfCRTK1 variant to transport CQ and the magnitude of in vitro CQ resistance exhibited by the
respective parasite line (R2 value of 0.856; S2A Fig). We conclude that the mutations which
suppress the quinine-hypersensitivity of the 106/176I line (C72R, Q352K, or Q352R) simulta-
neously re-sensitize the parasite to CQ by abrogating the protein’s capacity to efflux CQ from
the DV. Likewise, a mutation that suppresses the hypersensitivity of 106/176I parasites to aman-
tadine (V369F), also caused a marked reduction in the ability of 76I-PfCRTK1 to transport CQ,
which explains why the 106/176I,369F line displayed a relatively low level of resistance to CQ.
Similar results were obtained when we examined the uptake of [3H]quinine and [3H]quini-
dine (Fig 2B and 2C and S2 Fig). That is, the capacities of the different PfCRTK1 isoforms to
transport quinine or quinidine generally correlated with the in vitro responses of the parasite
lines to these drugs. Key exceptions included the quinine hypersensitivities of the 106/176I
and 106/176I,369F lines, which were not readily reconciled with the low quinine transport activ-
ity of 76I-PfCRTK1 and the lack of quinine transport via 76I,369F-PfCRTK1, respectively.
The modest capacity of 76I-PfCRTK1 for quinine transport was nonetheless abolished by the
Fig 1. Isoforms of PfCRTK1 localize to the surface of Xenopus oocytes. (A) Immunofluorescence microscopy was used to localize PfCRT in the
oocyte. In each case, the expression of the PfCRT variant resulted in a fluorescent band external to the pigment layer, indicating that the protein was
expressed in the oocyte plasmamembrane. The band was not present in noninjected oocytes. The images are representative of at least two independent
experiments (performed using oocytes from different frogs), within which images were obtained from a minimum of three oocytes per oocyte type. (B) The
level of PfCRT protein in the oocyte membrane was semiquantified using a western blot method [42]. The analysis included PfCRTK1 as a positive
control, to which the other band intensity values were normalized. The data are the mean + SEM of at least five independent experiments (performed
using oocytes from different frogs), within which measurements were averaged from two independent replicates. There were no significant differences in
expression levels between constructs (P > 0.05; one-way ANOVA); hence, all of the PfCRT variants were present at similar levels in the oocyte
membrane.
doi:10.1371/journal.ppat.1005725.g001
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introduction of C72R, Q352K, or Q352R. Another exception was the moderate ability of
76N-PfCRTK1 to transport quinidine, which was at odds with the sensitivity of 106/176N para-
sites to this drug.
Together, these findings revealed a strong relationship between the magnitude of CQ, qui-
nine, or quinidine resistance exhibited by a given 106/1 or K1 parasite and the capacity of its
PfCRT protein for mediating the efflux of the respective drug from the DV. However, the
mechanism underpinning the quinine-hypersensitivity caused by the introduction of T76I into
PfCRTK1, and why the subsequent addition of C72R, Q352K, or Q352R negates this response,
remained unclear.
High-affinity binding of quinine to 76I-PfCRTK1 causes hypersensitivity
to quinine
We undertook experiments to determine whether the kinetics of 76I-PfCRTK1- and 76N-
PfCRTK1-mediated transport could explain why these proteins cause unexpected responses to
quinine and quinidine, respectively. All of the PfCRTK1 isoforms we had identified as possess-
ing significant CQ, quinine, or quinidine transport activity (Fig 2A–2C) were included for
study. The resulting Michaelis-Menten plots (S3 Fig) yielded a Michaelis–Menten constant
(Km) and maximum velocity (Vmax) for each drug and PfCRT isoform (Table 2). Across all
three drugs, the Km values increased in the order 76I-PfCRT
K1< PfCRTK1< 76N-PfCRTK1,
whereas the Vmax values increased in the order 76I-PfCRT
K1< 76N-PfCRTK1 PfCRTK1.
Thus, we conclude that T76I increases the affinity of PfCRTK1 for its quinoline substrates, but
Fig 2. CQ, quinine, and quinidine transport activities differ significantly between isoforms of PfCRTK1. Noninjected oocytes accumulate low
levels of CQ, quinine, and quinidine via simple diffusion of the neutral species of the drug [29, 30]. This represents the background level of drug
accumulation. In all cases, the concentration of the [3H]drug under study was 0.25 μM. (A) The uptake of [3H]CQ was measured at pH 6.0 and in the
presence of 15 μM unlabeled CQ. The rates of CQ uptake (pmol per oocyte/h) in noninjected oocytes and oocytes expressing PfCRTK1 were 0.98 ± 0.13
and 6.75 ± 0.94, respectively. (B, C) The uptake of [3H]quinine or [3H]quinidine was measured at pH 5.0 and in the presence of 1 μM of the respective
unlabeled drug. The rates of uptake (pmol per oocyte/h) in noninjected oocytes and oocytes expressing PfCRTK1 were 0.10 ± 0.01 and 0.55 ± 0.03,
respectively, for quinine and 0.063 ± 0.010 and 0.38 ± 0.08, respectively, for quinidine. Note that the relatively low total concentration of quinine and
quinidine (1.25 μM) used in these assays enabled the detection of [3H]quinine transport via the 76I-PfCRTK1 isoform. However, this low drug
concentration also resulted in rates of quinine and quinidine transport that were 10–15 times lower than those measured for CQ (a difference which
corresponds well with the ~12-fold reduction in the total concentration of quinine or quinidine relative to the total concentration of CQ). In all panels, drug
uptake is expressed relative to that measured in oocytes expressing PfCRTK1 and the data are the mean + SEM of at least five independent
experiments (performed using oocytes from different frogs), within which measurements were made from 10 oocytes per treatment. The asterisks
denote a significant difference in drug uptake between the noninjected treatment and that measured in oocytes expressing a variant of PfCRT:
*P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA).
doi:10.1371/journal.ppat.1005725.g002
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that this change is accompanied by a significant decrease in its maximum rate of transport. By
contrast, T76N consistently decreased the affinity of PfCRTK1 for its quinoline substrates, and
either had little effect on the Vmax (quinine) or caused a marked reduction in the Vmax (CQ
and quinidine). Interestingly, the introduction of V369F into 76I-PfCRTK1 significantly
reduced the protein’s affinity for CQ (from 247 to 415 μM) and further reduced its maximum
rate for CQ transport (from 29.3 to 13.8 pmol per oocyte/h), while also abrogating its ability to
transport quinine and quinidine (Fig 2B and 2C). Our finding that 76I,369F PfCRTK1 is a very
low-affinity and low-capacity transporter of CQ is again consistent with the modest level of
CQ resistance exhibited by the 106/176I,369F parasite line.
Remarkably, we found that 76I-PfCRTK1 possesses an extraordinarily high affinity for qui-
nine and an extraordinarily low Vmax for quinine transport; its Km was ~70 times lower, and its
Vmax ~115 times lower, than the value obtained for PfCRT
K1. This combination of kinetic
properties indicates that 76I-PfCRTK1 binds extremely tightly to quinine and only occasionally
translocates the drug. Thus, quinine will clog the binding site of 76I-PfCRTK1, which should
greatly diminish the ability of the protein to transport its natural substrate. These findings sug-
gest that quinine-hypersensitivity results from quinine exerting two killing effects in 106/176I
parasites—the inhibition of hemozoin formation and the inhibition of PfCRT’s normal physio-
logical role (which is essential for parasite survival [39, 40]). The low level of quinine transport
mediated by 76I-PfCRTK1 was not detected following the introduction of C72R, Q352K,
Q352R, or V369F (Fig 2B). Of these mutations, Q352R and Q352K each fully return 106/176I
parasites to quinine-sensitive status, C72R causes a substantial but incomplete rescue from qui-
nine-hypersensitivity, and V369F confers a modest but significant suppression of the parasite’s
hypersensitivity to quinine (Table 1). Taken together, our data indicate that the insertion of a
positively-charged residue into the substrate-binding cavity of 76I-PfCRTK1 greatly diminishes
or abolishes its interaction with quinine (and its ability to transport CQ and quinidine), thereby
reversing the parasite’s hypersensitivity to quinine (and simultaneously re-sensitizing it to CQ
and quinidine). Our finding that these effects are achieved to a much lesser degree by V369F,
which instead introduces a bulky hydrophobic residue into 76I-PfCRTK1, indicates that elec-
trostatic repulsion is the key mechanism underpinning the dramatic decrease in the protein’s
ability to bind and translocate protonated quinolines.
Table 2. Kinetic parameters for the transport of CQ, quinine, and quinidine via variants of PfCRTK1.
PfCRT variant Apparent Km (μM)
a,b Apparent Vmax (pmol per oocyte/h)
CQ Quinine Quinidine CQ Quinine Quinidine
PfCRTK1 282 ± 5 (9) 28.8 ± 2.7 (7) 84 ± 1 (6) 72 ± 3 (9) 10.3 ± 0.8 (7) 24.4 ± 1.6 (7)
76N-PfCRTK1 303 ± 5e,f (7) 41.0 ± 2.6f (6) 94 ± 4c,f (6) 48.0 ± 4.5c,f (7) 13.0 ± 1.0d,f (6) 14.1 ± 0.9e,g (6)
76I-PfCRTK1 247 ± 7c,f (5) 0.42 ± 0.04c,f (4) 24.1 ± 3.0f (6) 29.3 ± 7.2c,f (5) 0.09 ± 0.01c,f (4) 7.2 ± 0.5e,g (6)
76I,369F-PfCRTK1 415 ± 25c (5) n.d. n.d. 13.8 ± 1.3c (5) n.d. n.d.
aPfCRT-mediated transport was calculated by subtracting the uptake of drug measured in the control oocytes (oocytes expressing 76K-PfCRTK1) from that
in oocytes expressing PfCRTK1, 76N-PfCRTK1, 76I-PfCRTK1, or 76I,369F-PfCRTK1. The data are shown in S3 Fig.
bAll values are the mean ± SEM of multiple independent experiments (performed using oocytes from different frogs), within which measurements were made
from 10 oocytes per treatment. The exact n values are indicated in parentheses.
The P values determined from an ANOVA were less than c0.001, d0.01, or e0.05 for comparisons with PfCRTK1 within the same drug treatment and kinetic
parameter.
The P values determined from an ANOVA were less than f0.001 or g0.01 for comparisons between 76N-PfCRTK1 and 76I-PfCRTK1 within the same drug
treatment and kinetic parameter.
doi:10.1371/journal.ppat.1005725.t002
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Our kinetic analyses also revealed that 76N-PfCRTK1 is unique in being both a low-affinity
and a low-capacity transporter of quinidine. By comparison, PfCRTK1 mediated the low-affin-
ity but high-capacity transport of quinidine, and 76I-PfCRTK1 was a high-affinity, low-capacity
transporter of quinidine. Thus, the sensitivity of 106/176N parasites to quinidine is likely due to
the inability of 76N-PfCRTK1 to decrease the concentration of quinidine within the DV to sub-
toxic levels.
I356T increases quinine transport via 76I-PfCRTK1
We recently reported [42] that the CQ transport activity of PfCRTK1 is ~20% higher than that
of PfCRTDd2, even though the two proteins differ only at position 356 (Table 1). However, the
I356T mutation also demonstrated epistasis. That is, depending on the nature and number of
the mutations already present, its introduction increased, decreased, or had no effect on the
ability of PfCRT to transport CQ [42]. We therefore investigated whether the introduction of
I356T decreases the ability of PfCRTK1 variants to transport quinine and quinidine. We mea-
sured the uptake of [3H]quinine or [3H]quinidine in oocytes expressing either a PfCRTK1
variant (PfCRTK1, 76N-PfCRTK1, or 76I-PfCRTK1) or its I356T counterpart (PfCRTDd2,
76N-PfCRTDd2, or 76I-PfCRTDd2). Consistent with our previous observation with CQ trans-
port, we found that the rate of quinine and quinidine uptake mediated by PfCRTK1 was 17–
35% greater than that measured for PfCRTDd2 (S4 Fig). Moreover, we observed the same rela-
tionship, only considerably more exaggerated, between the 76N variants of PfCRTK1 and
PfCRTDd2 and, in the case of quinidine transport, between 76I-PfCRTK1 and 76I-PfCRTDd2.
The single exception to this pattern was quinine transport via 76I-PfCRTK1, which showed a
30–40% decrease relative to its PfCRTDd2 counterpart. Our findings establish a key role for
position 356 in the attainment of a high level of quinoline transport activity, but also confirm
the epistatic nature of this position.
Isoforms of PfCRT from amantadine-hypersensitive parasites transport
amantadine
We next sought to understand why CQ-resistant parasites are hypersensitive to amantadine
and how certain mutations in PfCRT (e.g., T76K, S163R, or V369F) countercheck this
response. Given that we had already ascertained that the PfCRTK1 variants carrying T76K or
S163R do not possess significant quinoline transport activity (Fig 2A–2C), we focused our ini-
tial investigations on 76I,369F-PfCRTK1, as it mediates a detectable level of CQ transport. To
test the possibility that hypersensitivity to amantadine is due to it clogging the substrate-bind-
ing cavity of PfCRT, and that this effect is alleviated by the addition of V369F, we compared
the ability of unlabeled amantadine to inhibit the transport of [3H]CQ via 76I-PfCRTK1 and
76I,369F-PfCRTK1 (Fig 3A). Somewhat surprisingly, there was little difference in the resulting
half-maximum inhibitory concentrations (IC50s; listed in Fig 3A). Moreover, these IC50s were
much higher than those obtained in the oocyte system for established inhibitors of PfCRTCQR,
such as the quinine dimer Q2C (1.4 ± 0.2 μM [46]), saquinavir (13 ± 1 μM [47]), and verapamil
(30 ± 3 μM [30]). Since amantadine is a relatively low-affinity inhibitor of both 76I-PfCRTK1
and 76I,369F-PfCRTK1, it is unlikely that the hypersensitivity of CQ-resistant parasites to
amantadine is due to it exerting an anti-PfCRTCQR effect.
This result led us to examine whether amantadine hypersensitivity is instead a consequence
of significant changes in the ability of PfCRT to transport amantadine. We found that oocytes
expressing PfCRTK1 or 76I-PfCRTK1 showed a marked increase in [3H]amantadine accumula-
tion relative to noninjected oocytes (Fig 3B and 3C). By contrast, oocytes expressing 76K-
PfCRTK1 or 163R,356V-PfCRTK1 failed to take up [3H]amantadine above the background level
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Fig 3. Isoforms of PfCRTK1 from amantadine-hypersensitive parasites transport amantadine. (A) Amantadine inhibits the transport of [3H]CQ
via 76I-PfCRTK1 and 76I,369F-PfCRTK1 in a concentration-dependent manner (IC50s of 186 ± 16 and 174 ± 26 μM, respectively). (B) The uptake of
[3H]amantadine (0.146 μM) in the absence and presence of verapamil or saquinavir. The measurements were undertaken at pH 5.0 and in the
presence of 50 μM unlabeled amantadine. (C) The PfCRT-mediated transport of [3H]amantadine. Using the data shown for the solvent control in
panel B, the component of [3H]amantadine transport attributable to PfCRT was calculated by subtracting the background level of accumulation (i.e.,
the average of the uptake measured in noninjected oocytes and oocytes expressing 76K-PfCRTK1) from that measured for each of the oocyte types.
The rates of amantadine uptake (nmol per oocyte/h) in noninjected oocytes and PfCRTK1-expressing oocytes were 5.4 ± 0.9 and 12 ± 2.8,
respectively. The asterisks denote a significant difference from the noninjected control: *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA). (D)
Trans-stimulation of PfCRT-mediated [3H]CQ transport by unlabeled amantadine. The oocytes were microinjected with a buffer control or with buffer
containing amantadine, spermine, or histidine. The estimated intracellular concentrations ([compound]i) are indicated. The asterisks denote a
significant difference from the relevant buffer-injected control. (E) Concentration-dependence of the trans-stimulation of [3H]CQ uptake by
amantadine. The oocytes were microinjected with buffer containing amantadine to achieve an estimated [amantadine]i of 1 to 20 mM. The app Km and
app Vmax values are the apparent kinetic parameters for the trans-stimulatory effect of amantadine. The data show CQ uptake above that measured in
the relevant buffer-injected control; the total rates of CQ uptake are presented in S6 Fig. The noninjected data overlays the data obtained with oocytes
expressing PfNT1, PfCRT3D7, or 76K-PfCRTK1. (F) A magnified plot of the 76I-PfCRTK1 and 76I,369F-PfCRTK1 data from panel E. In all panels, the
data are the mean ± SEM of five independent experiments (performed using oocytes from different frogs), within which measurements were made
from 10 oocytes per treatment. Where not shown, error bars fall within the symbols.
doi:10.1371/journal.ppat.1005725.g003
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of accumulation, and 76I,369F-PfCRTK1 displayed only a very low (but statistically significant)
level of amantadine transport activity. Moreover, [3H]amantadine transport via PfCRTK1,
76I-PfCRTK1, and 76I,369F-PfCRTK1 was inhibited by the PfCRTCQR inhibitors verapamil and
saquinavir. These findings suggest that hypersensitivity to amantadine arises from the ability of
PfCRTCQR isoforms to transport amantadine, and that mutations such as T76K, S163R, and
V369F reverse this response by substantially decreasing or abolishing amantadine transport
activity.
The signal-to-background ratio we obtained for [3H]amantadine transport in the oocyte
system was around 2 (Fig 3B), which is relatively modest when compared with that obtained
for quinine and quinidine transport (which typically produce ratios of 4–7; e.g., Fig 2B and 2C
and S4 Fig) or CQ transport (which typically produces a ratio of 8–25; e.g., Figs 2A and 3D and
S5 Fig). We therefore interrogated the amantadine transport properties of PfCRT further by
conducting a series of trans-stimulation experiments. Many transporters reorientate more
quickly from one face of the membrane to the other when a substrate is bound compared with
when the transporter is empty. Transporters that display this characteristic can be trans-stimu-
lated; in the case of PfCRTCQR, the uptake of [3H]CQ from the external solution will be accel-
erated by the presence of an unlabeled substrate on the cytosolic face of the membrane. We
therefore measured the uptake of [3H]CQ into oocytes which had been microinjected with a
buffer control or with buffer containing unlabeled amantadine, spermine, or histidine. Sper-
mine (a polycation) and histidine (a weak base) do not appear to interact with PfCRTDd2 (S5
Fig and Martin et al. [30]) and were therefore included as extra negative controls. In addition,
oocytes expressing an unrelated P. falciparum transporter (the nucleoside transporter PfNT1
[48]) were included as a further negative control. We found that amantadine did not affect
the accumulation of [3H]CQ in noninjected oocytes or oocytes expressing 76K-PfCRTK1,
PfCRT3D7, or PfNT1 (Fig 3D). Moreover, neither spermine nor histidine altered [3H]CQ
uptake in any of the oocyte types. By contrast, amantadine trans-stimulated the transport of
[3H]CQ into oocytes expressing PfCRTK1, PfCRTDd2, 76I-PfCRTK1, or 76I,369F-PfCRTK1,
albeit to different extents; the respective increases in the rate of CQ influx (in pmol per oocyte/
h) were 6.4 ± 0.2, 6.7 ± 0.3, 0.68 ± 0.04, and 0.43 ± 0.02. We extended this analysis by measur-
ing the concentration-dependence of the trans-stimulation of PfCRTK1, 76I-PfCRTK1, and
76I,369F-PfCRTK1 (Fig 3E and 3F and S6 Fig). A least-squares fit of the Michaelis-Menten
equation to the data yielded apparent kinetic parameters for the trans-stimulatory effect of
amantadine (listed in Fig 3). These results revealed that the addition of V369F to 76I-PfCRTK1
causes a 6.2- to 7.2-fold increase in the concentration of amantadine required for the half-max-
imal trans-stimulation of the transporter.
Taken together, our work shows that PfCRT variants from parasites that are hypersensitive
to amantadine possess the ability to transport this drug, and that the introduction of mutations
that suppress amantadine hypersensitivity either abolish (T76K and S163R) or substantially
decrease (V369F) the protein’s capacity for amantadine transport. These findings led us to pro-
pose that amantadine, which should sequester within the DV via weak-base trapping, exerts its
main antiplasmodial effect outside of the DV and that the PfCRT-mediated leak of the drug
back into the cytosol results in amantadine hypersensitivity. We therefore utilized a set of para-
site assays to test this hypothesis in situ.
PfCRT effluxes amantadine from the DV of amantadine-hypersensitive
parasites
The function of PfCRT can be investigated in its native environment by employing an assay that
indirectly detects the movement of protonated drugs out of the DV [34–36]. This method uses a
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fluorescent pH-sensitive probe to measure an outward leak of protons, which manifests as an
increase in the rate of alkalinization of the DV. A drug-induced proton leak arises when a weak-
base drug enters the acidic DV in its unprotonated form and is effluxed in its protonated form.
We applied this assay to a set of P. falciparum transfectants (the C2GC03, C4Dd2, and C67G8 lines
[2]) that are isogenic except for their pfcrt allele, which encodes either PfCRT3D7 (C2GC03) or a
PfCRTCQR isoform of the protein (PfCRTDd2 in C4Dd2 and PfCRT7G8 in C67G8). CQ was
included as a positive control and consistent with previous observations [34–36, 46], it increased
the rate of DV alkalinization in the CQ-resistant C4Dd2 and C67G8 lines and was without effect
in the CQ-sensitive C2GC03 line (Fig 4). We obtained similar results with amantadine and also
showed that verapamil inhibits the amantadine-associated leak of protons from the DV of
C4Dd2 and C67G8 parasites. These findings confirm that amantadine accumulates within the DV
Fig 4. Amantadine is a substrate of PfCRTDd2 and PfCRT7G8, and not of wild-type PfCRT, in situ. The
rate of concanamycin A-induced DV alkalinization (expressed as the inverse of the half-time for DV
alkalinization) in the C2GC03 (CQ-sensitive, expressing PfCRT3D7), C4Dd2 (CQ-resistant, expressing
PfCRTDd2), and C67G8 (CQ-resistant, expressing PfCRT7G8) transfectant lines was measured in the absence
and presence of amantadine (AMT), CQ, or verapamil (VP). The effect of amantadine on the DV alkalinization
rate was also measured in the presence of verapamil (final concentration of 50 μM). The drugs were added to
suspensions of saponin-isolated trophozoite-stage parasites containing fluorescein-dextran in their DVs 4
min before the addition of concanamycin A (100 nM). CQ was added at a concentration of 2.5 μM and the
concentration of amantadine was 10 μM. Consistent with previous studies, the addition of CQ elevated the
rate of alkalinization in both of the CQ-resistant lines and had a small buffering effect in the C2GC03 parasites
[34–36, 46]. The biological basis for the difference in the rate of CQ-dependent alkalinization between the two
CQ-resistant lines is currently unclear, but could be due to differences in (1) the expression of PfCRT, (2) the
transport properties of the two PfCRT isoforms, (3) the volume of the DV, and/or (4) the concentration of
PfCRT’s natural substrates within the DV. The data are the mean + SEM of five independent experiments
(performed on different days). The asterisks denote a significant difference from the relevant solvent control:
***P < 0.001 (one-way ANOVA).
doi:10.1371/journal.ppat.1005725.g004
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via weak-base trapping and also provide in situ evidence of the ability of PfCRTCQR isoforms to
transport amantadine back into the cytosol.
If amantadine hypersensitivity results from the PfCRT-mediated efflux of the drug from the
DV, we would expect that inhibitors of PfCRTCQR would reduce this response. We tested
this hypothesis by determining the susceptibility of the isogenic lines to amantadine in the
absence and presence of verapamil or chlorpheniramine [49] (another established inhibitor of
PfCRTCQR). These experiments, which included CQ as a control as well as CQ-resistant (Dd2)
and CQ-sensitive (3D7) reference strains, entailed using a fluorescence-based method to mea-
sure parasite growth in the presence of increasing concentrations of amantadine or CQ. The
resulting IC50s (Table 3) provided two salient findings. First, the data verified the striking
hypersensitivity of CQ-resistant parasites to amantadine. Secondly, in all cases this hypersensi-
tivity was partially suppressed by the PfCRT inhibitors. Thus, we conclude that the hypersensi-
tivity of the 106/176I line, and of other CQ-resistant parasites, to amantadine arises from the
PfCRTCQR-mediated redistribution of the drug from the DV into the cytosol, where it gains
better access to its main antiplasmodial target.
Discussion
Our work provides mechanistic explanations for the patterns of inverse susceptibility induced
by PfCRT. First, we confirmed our previous observation [42] of there being a positive correla-
tion between the capacity of a given PfCRT isoform for mediating CQ transport and the mag-
nitude of CQ resistance achieved by the respective parasite (S7A Fig) and extended this
relationship to include, with the notable exception of the QN-hypersensitive lines, a positive
correlation between the quinine or quinidine transport activity of PfCRT and the parasite’s in
vitro responses to these drugs (Fig 5A and S7B Fig). Moreover, we showed that in most cases,
the isoforms of PfCRTK1 that possessed CQ transport activity also transported quinine and
quinidine and vice versa. Together, these findings confirm a common role for PfCRT in reduc-
ing the accumulation of CQ, quinine, and quinidine within the DV and explain the tendency of
CQ-resistant parasites to exhibit decreased susceptibilities to quinine and quinidine. However,
Table 3. In vitro antiplasmodial activities of CQ and amantadine against CQ-sensitive and CQ-resistant P. falciparum parasites.
Strain/lineb IC50
a
CQ (nM)c Amantadine (μM)c
Control + 1 μM VP + 1 μM CP Control + 1 μM VP + 1 μMCP
3D7 25 ± 1.1 24 ± 0.9 22 ± 0.7 344 ± 8.9 352 ± 9.1 351 ± 11
Dd2 151 ± 4.8d 25 ± 1.0g 11 ± 0.04g 11 ± 0.1d 55 ± 0.6f 64 ± 0.9g
C2GC03 27 ± 1.6 26 ± 1.3 22 ± 3.1 335 ± 9.5 341 ± 11 348 ± 13
C4Dd2 149 ± 4.6d 26 ± 0.09g 18 ± 0.01g 8.4 ± 0.06d 57 ± 0.6g 66 ± 1.0g
C67G8 87 ± 2.1d 25 ± 0.2g 20 ± 0.06g 43 ± 2.9d 78 ± 4.3e 88 ± 5.4f
aThe IC50 values are the mean ± SEM of five independent experiments (performed on different days), within which measurements were averaged from 3
replicates.
bField-derived strains: 3D7 (CQ-sensitive; Africa); Dd2 (CQ-resistant; Indochina/Laos). Isogenic pfcrt transfectant lines: C2GCO3 (CQ-sensitive); C4Dd2 (CQ-
resistant); C67G8 (CQ-resistant).
cMeasurements were made in the absence and presence of verapamil (VP) or chlorpheniramine (CP).
dThe P values determined from a one-way ANOVA were less than 0.001 for comparisons with the relevant CQ-sensitive strain or line (and within either the
CQ or amantadine treatment).
The P values determined from a one-way ANOVA were less than e0.001, f0.01, or g0.05 for comparisons between the control treatment and the relevant VP
or CP treatment from the same strain or line.
doi:10.1371/journal.ppat.1005725.t003
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our results resolve this phenomenon further by providing a fundamental insight into PfCRT-
induced drug phenotypes: whether a given isoform of PfCRT alters the parasite’s susceptibility
to a drug, and to what extent and in which direction, depends on the kinetics of the drug’s
transport via PfCRT.
A key example of this principle is the quinine-hypersensitivity conferred by 76I-PfCRTK1.
Our work reveals that the introduction of 76I into PfCRTK1 has the remarkable effect of trans-
forming the protein into an exceedingly high-affinity, low-capacity transporter of quinine.
These highly abnormal kinetic properties will cause the drug to clog PfCRT’s substrate-binding
cavity, which should block the transport of the natural substrate and thereby prevent the pro-
tein from fulfilling its essential physiological role (Fig 5A). Thus, we propose that hypersensi-
tivity to quinine results from the drug exerting at least two killing effects in 106/176I parasites—
anti-hemozoin and anti-PfCRTCQR. This hypothesis provides mechanistic explanations
for two previously abstruse observations: (1) despite dramatic differences in their quinine
responses, 106/176I and 106/1 parasites accumulate similar levels of quinine [11] and (2) qui-
nine and CQ produce a synergistic interaction in 106/176I parasites, whereas a slightly antago-
nistic interaction occurs in the 106/176T line [12]. In the case of the first observation, the lack
of a difference in quinine accumulation concurs with the exceedingly low capacity of 76I-
PfCRTK1 for transporting quinine. In regard to the second phenomenon, the synergistic inter-
action in 106/176I is readily reconcilable with the ability of quinine to adhere to the binding cav-
ity of 76I-PfCRTK1, as this should both inhibit the normal function of the protein and block
Fig 5. Molecular mechanisms for the drug hypersensitivities induced by PfCRT isoforms in the malaria parasite. (A) The variants of PfCRTK1 that
contain 72R, 76K, 163R, 352K, or 352R (R/K) do not possess significant quinine (QN) transport activity. The drug would therefore remain in the parasite’s
DV where it exerts an anti-hemozoin effect that kills the parasite, which is consistent with the QN-sensitive (S) status of the respective lines. PfCRTK1
(76T) is able to transport QN out of the DV and thereby imparts low-level resistance (low-R) to QN. By contrast, 76I-PfCRTK1 has an extremely high
affinity for QN coupled with an extremely low maximum rate of transport. This causes QN to clog the binding site of 76I-PfCRTK1, thereby blocking the
transport of the natural substrate. Hence, the QN-hypersensitivity (hyper-S) observed in 106/176I parasites results from QN exerting two killing effects—
anti-hemozoin and anti-PfCRTCQR. The gain of a positively-charged residue at position 72 or 352 (76I R/K) prevents the interaction of the transporter with
QN and returns the parasites to QN-sensitive status. (B) Amantadine (AMT) is a relatively poor inhibitor of both 76I-PfCRTK1 and 76I,369F-PfCRTK1,
making it unlikely that the AMT-hypersensitivity of CQ-resistant parasites is due to an anti-PfCRTCQR effect. The isoforms of PfCRT from AMT-
hypersensitive parasites (PfCRTK1 and 76I-PfCRTK1) have the ability to transport this weak-base drug out of the DV (where it accumulates) whereas
those from AMT-sensitive parasites either do not possess significant AMT transport activity (e.g., 76K-PfCRTK1 and 163R,356V-PfCRTK1; R/K) or
transport AMT with low affinity and low capacity (76I,369F-PfCRTK1). The data therefore converge on a scenario in which AMT exerts its main antimalarial
activity in the cytosol and AMT-hypersensitivity arises from the redistribution of the drug from the DV into the cytosol via a PfCRTCQR variant (e.g.,
PfCRTK1 or 76I-PfCRTK1).
doi:10.1371/journal.ppat.1005725.g005
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the efflux of CQ from the DV. The slightly antagonistic effect observed in the 106/176T para-
sites is likely to result from the two drugs competing to bind to heme (CQ is the more potent
inhibitor of hemozoin formation [25, 27]) and/or other differences in their activities (e.g., CQ
also appears to inhibit the glutathione-dependent degradation of heme, whereas quinine is
thought to lack this activity [50]).
Cooper and colleagues reported a third perplexing characteristic of the 106/176I line that may
likewise arise from quinine’s ability to block the normal function of 76I-PfCRTK1. The presence
of verapamil typically re-sensitizes CQ-resistant parasites to CQ (and to quinine and quinidine)
and this resistance-reversing effect was evident for all three drugs in the 106/176T and 106/176N
lines [11, 12]. It was also apparent in the 106/176I parasites, but only in the CQ and quinidine
treatments. In the quinine treatment, verapamil exerted the opposite effect; i.e., it decreased the
sensitivity of the 106/176I line to quinine and thus partially suppressed the parasite’s hypersensi-
tivity to this drug [11, 12]. One possible explanation for this highly unusual observation is a sce-
nario in which verapamil competes with quinine for binding to 76I-PfCRTK1, and that the
natural substrate is better able to access the translocation pore when verapamil is bound relative
to when quinine is bound. Given that the substrate-binding site of PfCRTDd2 has been shown to
behave as a large polyspecific cavity that can bind at least two molecules simultaneously [29], it
is conceivable that verapamil and quinine interact with the binding cavity differently and that
verapamil presents somewhat less of an obstacle to the transport of the natural substrate via
76I-PfCRTK1 than does quinine. Such a scenario would provide a mechanistic explanation for
the verapamil-induced reduction in quinine’s activity against the 106/176I line.
We recently reported that CQ-resistant parasites are hypersensitive to dimers of quinine,
and that this appears to be due to these molecules inhibiting both heme detoxification and
PfCRTCQR function (the quinine dimers are potent inhibitors of PfCRTDd2 but are not translo-
cated by the transporter) [46]. Hence, the anti-PfCRTCQR activity of quinine in the 106/176I
parasites is not simply an intriguing but extraneous biological oddity; it signifies that one of the
parasite’s key modulators of drug resistance is itself a druggable antimalarial target.
Our findings suggest that less dramatic changes in the kinetics of transport via PfCRT can
also significantly affect the parasite’s response to a drug. 76N-PfCRTK1 decreases the parasite’s
susceptibility to CQ and quinine while being without effect on its response to quinidine [11,
12, 14]. A simple interpretation of these observations would be that 76N-PfCRTK1 transports
CQ and quinine but fails to recognize quinidine. However, we found that 76N-PfCRTK1 main-
tains the ability to transport quinidine, but that its affinity for the drug is slightly reduced, and
that its maximum rate of quinidine transport is significantly reduced, relative to the kinetics of
quinidine transport via PfCRTK1. The low-capacity, low-affinity nature of quinidine transport
via 76N-PfCRTK1 will limit the protein’s ability to reduce the accumulation of the drug within
the DV and hence could explain why 76N-PfCRTK1 has little net effect on the parasite’s suscep-
tibility to quinidine (S7B Fig).
The hypersensitivity of CQ-resistant parasites to amantadine was first reported several
decades ago [13], but the molecular basis for this phenomenon has remained unknown. We
demonstrate that amantadine hypersensitivity cannot be explained by an anti-PfCRTCQR effect
and is instead attributable to a second mechanism. Our work shows that amantadine sequesters
within the acidic environment of the DV and that the hypersensitivity of CQ-resistant parasites
to amantadine results from the ability of PfCRTCQR isoforms to efflux the drug from the DV
into the parasite cytosol (Fig 5B). These findings indicate that amantadine acts on a target out-
side of the DV and that it exerts its antiplasmodial activity to greater effect when proteins such
as PfCRTDd2, PfCRT7G8, PfCRTK1, and 76I-PfCRTK1 leak the accumulated drug back into the
cytosol. The antiviral target of amantadine is a proton channel [51] and it is possible that the
drug likewise targets an essential cation channel or transporter in the parasite.
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All of the mutations that introduced a positively-charged residue into PfCRTK1 abolished its
ability to transport CQ, quinine, quinidine, and amantadine. Hence, in addition to confirming
the importance of electrostatic repulsion in preventing interactions between PfCRT and pro-
tonated drugs, our results suggest that the transporter’s ability to transport protonated quino-
lines out of the DV (and thereby confer quinoline resistance) is fundamentally connected to its
ability to transport protonated amantadine out of the DV (and thereby induce amantadine
hypersensitivity). Furthermore, the detection in field isolates of T76K, C72R, or S163R in oth-
erwise PfCRTCQR isoforms [5] indicates that these types of changes could be occurring in the
parasite population in response to selection forces exerted by other drugs and/or because, in
the absence of CQ, these parasites are fitter than their CQ-resistant counterparts (most
PfCRTCQR isoforms impart a fitness cost [52–55]). Such a phenomenon appears to have taken
place in French Guiana; Pelleau and colleagues [56] recently showed that another mutation
that introduces a positive charge into PfCRTCQR (C350R) emerged in a CQ-resistant popula-
tion following the withdrawal of CQ and is attributed with reinstating these parasites to CQ-
sensitive status.
Our findings also provide a foundation for understanding and exploiting clinically-relevant
cases of reciprocal collateral sensitivity. Most of the current treatments for uncomplicated
malaria are combination therapies that pair an artemisinin derivative (all of which are metabo-
lised into dihydroartemisinin) with a quinoline-related partner drug—of which the most
widely used is lumefantrine [57]. Cases of severe malaria, as well as Plasmodium-infected preg-
nant women, are typically treated with combinations that include an antibiotic, such as clinda-
mycin. It is, therefore, worth noting that several in vitro studies have observed isoforms of
PfCRTCQR to induce hypersensitivity to lumefantrine (with 1.5–3.2-fold decreases in the IC50
[16, 17, 56, 58–61]), artemisinin and/or dihydroartemisinin (with 1.9–3.7-fold decreases in the
IC50 [6, 11, 17, 58, 59, 62]) as well as to a number of antibiotics [10, 63–67]—including clinda-
mycin [10, 63, 65, 68]. Moreover, multiple clinical trials undertaken in malarious regions
throughout the world have associated the wild-type protein (i.e., PfCRT3D7) with significant
reductions in the parasite’s susceptibility to artemether-lumefantrine [16, 69–71], such that (1)
the administration of artemether-lumefantrine was found to cause significant selection of CQ-
sensitive parasites carrying PfCRT3D7 and (2) the presence of parasites carrying PfCRT3D7
prior to artemether-lumefantrine treatment was associated with an increased risk of recrudes-
cence. It is possible that the hypersensitivity of CQ-resistant parasites to lumefantrine, the arte-
misinins, and/or to the antibiotics results from one of the mechanisms we describe in this
study. For instance, the antibiotics are either known or expected to act on targets outside of the
DV [63, 72, 73], but due to their weak-base nature, these drugs will sequester within the acidic
environment of this organelle. Hence, it is plausible that the antibiotics gain greater access to
their antimalarial target by being transported into the cytosol via PfCRTCQR. For these antibi-
otics as well as for lumefantrine and the artemisinins, and for the many other pharmacons that
display enhanced activity against CQ-resistant parasites, the set of assays outlined in our study
offer the means to determine which of the two mechanisms are involved, or whether an alto-
gether different mechanism is responsible. Such insights have the potential to contribute to the
formulation of rational approaches for maintaining and extending the useful lifespan of many
antimalarials by exploiting the opposing selection forces they exert upon PfCRT.
Materials and Methods
Generation of PfCRT coding sequences and synthesis of cRNA
The coding sequences of the different isoforms of PfCRT were generated via site-directed
mutagenesis using the primer pairs listed in S1 Table and an approach described previously
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[42]. The mutations were introduced into a codon-harmonized version of the PfCRT sequence
that had been inserted into the pGEM-He-Juel oocyte expression vector [74]. This sequence
encodes a version of PfCRT that is free of endosomal-lysosomal trafficking motifs and which is
therefore expressed at the plasma membrane of Xenopus laevis oocytes [30, 42]. All of the
resulting coding sequences were verified by sequencing (undertaken by the ACRF Biomolecu-
lar Resource Facility, ANU). The plasmids were linearized with SalI (ThermoFisher Scientific)
and 5’-capped complementary RNA (cRNA) was synthesized using the mMessage mMachine
T7 transcription kit (Ambion), and then purified with the MEGAclear kit (Ambion).
Harvest, preparation, and microinjection of X. laevis oocytes
Ethical approval of the work performed with the X. laevis frogs was obtained from the Austra-
lian National University Animal Experimentation Ethics Committee (Animal Ethics Protocol
Number A2013/13) in accordance with the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes. Oocytes were harvested and prepared as described in full else-
where [9]. Briefly, sections of ovary were harvested from adult female frogs (purchased from
NASCO) via a minor surgical procedure and single, de-folliculated oocytes were prepared
using collagenase D (Roche). Stage V-VI oocytes were microinjected with cRNA (20 ng per
oocyte) encoding PfCRT or PfNT1 and were stored at 16–18°C in OR2+ buffer (82.5 mMNaCl,
2.5 mM KCl, 1 mMMgCl2, 1 mMNa2HPO4, 5 mMHEPES, 1 mM CaCl2, and 50 μg/mL genta-
mycin; pH 7.8).
Oocyte membrane preparation and western blot analysis
The preparation of oocyte membranes and the semi-quantification of PfCRT protein was car-
ried out using a protocol described in detail elsewhere [42]. Protein samples prepared from
oocyte membranes were separated on a 4–12% Bis-Tris SDS-polyacrylamide gel (Life Technol-
ogies) and transferred to a Protran 0.45 μM nitrocellulose membrane (Amersham, GE
Healthcare Life Sciences). The membranes were probed with rabbit anti-PfCRT antibody (con-
centration of 1:4,000; Genscript) followed by horseradish peroxidase-conjugated goat anti-rab-
bit antibody (1:8,000; Life Technologies, cat. no. 656120). Validation of the specificity of the
anti-PfCRT antibody has been published in detail elsewhere [42]. The PfCRT band for each
variant was detected by chemiluminescence (Pierce), quantified using the Image J software
[75], and expressed as a percentage of the intensity measured for the PfCRTK1 band. Total pro-
tein staining was used to evaluate sample loading and efficiency of transfer as outlined previ-
ously [42]. Between five and seven independent experiments were performed (on oocytes from
different frogs), and in each experiment measurements were averaged from two independent
replicates.
Immunofluorescence of oocytes expressing PfCRT
Immunofluorescence analyses were performed on oocytes three days post-injection using a
method adapted fromWeise et al. [76]. Unless specified otherwise, both the incubation and
wash steps were conducted at room temperature with gentle shaking or rotation. The volume
of the incubation solution was 500 μL and the washes were performed with 1 mL of the speci-
fied solution. Six oocytes from each treatment type were fixed for 30 min in a solution of phos-
phate-buffered saline (PBS) and 4% v/v paraformaldehyde and then washed (10 min) three
times in PBS. The oocytes were permeabilized with 100% methanol for 20 min (-20°C, without
shaking) and washed (10 min) three times in PBS. A blocking solution (4% w/v bovine serum
albumin (BSA), 2% v/v normal goat serum (Life Technologies), and 0.1% v/v Triton X-100 in
PBS) was applied for 2 h, after which the oocytes were incubated overnight at 4°C in a second
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blocking solution (4% w/v BSA and 2% v/v normal goat serum in PBS). The samples were then
incubated for a further 4 h at room temperature before the blocking solution was replaced with
a solution containing the rabbit anti-PfCRT antibody (1:100 in 1.5% w/v BSA and 0.01% v/v
Triton X-100 in PBS) and the samples were incubated for 4 h at room temperature and then
overnight at 4°C. Three 10-min washes were performed in PBS supplemented with 1.5% w/v
BSA and all of the remaining steps were undertaken in the dark (and at room temperature).
The Alexa Fluor 488 donkey anti-rabbit antibody (1:500; Molecular Probes, cat. no. A-21206)
was incubated with the samples for 4 h in PBS supplemented with 4% w/v BSA and 2% v/v nor-
mal goat serum, after which three 10-min washes were performed in PBS.
The oocytes were post-fixed with paraformaldehyde (3.7% v/v in PBS) for 30 min, washed
twice (15 min) in 2 mL of PBS, and then dehydrated with a series of incubations in solutions of
increasing ethanol content. The solutions (in order of administration) were: 30% v/v ethanol in
PBS, 50% v/v ethanol in PBS, 70% v/v ethanol in ultrapure water, 90% v/v ethanol in ultrapure
water, and 100% ethanol. In each case, the samples were briefly washed in the ethanol-contain-
ing solution before a 15-min incubation was performed. A further two incubations in 100%
ethanol were conducted before the oocytes were embedded in an acrylic resin using the Tech-
novit 7100 plastic embedding system (Kulzer). Briefly, the samples were incubated with 500 μL
embedding solution (50% v/v Technovit 7100 in 100% ethanol) for 2 h, after which the oocytes
were incubated overnight in 500 μL of a second embedding solution (1% w/v Technovit 7100
‘hardener 1’ in Technovit 7100). A further two incubations (2 h each) were performed in the
second embedding solution before all of the solution was removed and 800 μL of a third
embedding solution (6.66% v/v Technovit 7100 ‘hardener 2’ and 1% w/v Technovit 7100 ‘hard-
ener 1’ in Technovit 7100) was added. After the samples had set (4 d), a microtome was used
to obtain ~4 μm slices, which were dried on microscope slides. Coverslips with a drop of Pro-
Long Gold Antifade Mountant (Life Technologies) were placed over the slices and sealed with
nail polish.
Images of the slices were obtained with a Leica Sp5 inverted confocal laser microscope
(Leica Microsystems) using the 63x objective. Excitation was achieved with a 488 nm argon
laser and the emissions were captured using a 500–550 nm filter. Images were acquired using
the Leica Application Suite Advanced Fluorescence software (Leica Microsystems). At least
two independent experiments were performed (on oocytes from different frogs) for each oocyte
type, within which slices were examined from a minimum of three oocytes. All of the slices
taken from oocytes expressing a PfCRT variant displayed a fluorescent band above the pigment
layer (i.e., consistent with the localization of PfCRT to the plasma membrane) that was not
present in noninjected oocytes.
Drug transport assays
The radiolabeled drugs were purchased from American Radiolabeled Chemicals ([3H]CQ,
[3H]quinine, and [3H]quinidine) or Moravek ([3H]amantadine). The uptake into oocytes of
[3H]CQ (0.25 μM; 20 Ci/mmol), [3H]quinine (0.25 μM; 20 Ci/mmol), [3H]quinidine
(0.25 μM; 20 Ci/mmol), or [3H]amantadine (0.146 μM; 137 mCi/mmol) was measured 3–6
days post-injection. Unless specified otherwise, the drug influx assays were conducted over
1.5–2 h at 27.5°C and in the presence of a low concentration of the unlabeled drug (CQ,
15 μM; quinine and quinidine, 1 μM; amantadine, 50 μM). The reaction buffer was either
ND96 pH 5.0 ([3H]quinine, [3H]quinidine, and [3H]amantadine transport assays) or ND96
pH 6.0 ([3H]CQ transport assays) and contained 96 mM NaCl, 2 mM KCl, 1 mMMgCl2, and
1.8 mM CaCl2 supplemented with either 20 mM homo-PIPES (pH 5.0 buffer) or 10 mMMES
and 10 mM Tris-base (pH 6.0 buffer). For each treatment, 10 oocytes were transferred to a 5
Mechanisms for PfCRT-Induced Drug Hypersensitivity
PLOS Pathogens | DOI:10.1371/journal.ppat.1005725 July 21, 2016 17 / 27
mL polystyrene round bottom tube (Falcon) and washed twice with 3.5 mL of ND96 buffer,
with the residual buffer removed by pipette. Influx commenced with the addition of 100 μL of
ND96 buffer supplemented with the radiolabeled and unlabeled drug and, where specified, an
unlabeled inhibitor (e.g., verapamil, saquinavir, or CQ). The assay was terminated by remov-
ing the reaction buffer with a pipette and washing the oocytes twice with 3.5 mL of ice-cold
ND96 buffer. Each oocyte was transferred to a separate well of a white 96-well plate (NUNC
or PerkinElmer), incubated overnight at room temperature in 30 μL of 10% SDS, and mixed
on an orbital shaker the following day for approximately 5 min. The lysed oocyte was then
combined with 150 μL of MicroScint-40 microscintillant (PerkinElmer), the plate covered
with a TopSeal-A (PerkinElmer), and the radioactivity measured with a PerkinElmer
MicroBeta2 microplate liquid scintillation analyzer.
Note that noninjected oocytes and oocytes expressing PfCRT3D7 take up [3H]CQ to similar
(low) levels via simple diffusion of the neutral species of the drug; this represents the ‘back-
ground’ level of [3H]CQ accumulation in oocytes (refer to Martin et al. [30] for full data and
discussion). There is also no detectable difference in the accumulation of [3H]quinine between
noninjected and PfCRT3D7-expressing oocytes, nor does the accumulation of [3H]quinidine
differ between these two oocyte types, and this background level of uptake has likewise been
attributed to simple diffusion [29, 30].
The kinetic parameters for CQ, quinine, and quinidine transport via different isoforms of
PfCRT (Table 1 and S3 Fig) were determined in SigmaPlot Windows Version 11.0 (Systat
Software Inc.) by a least-squares fit of the Michaelis-Menten equation (v = Vmax substrate]/
(Km + [substrate]) to the data.
The IC50 values presented in Fig 3A were determined in SigmaPlot by a least-squares fit of
the equation y = ymin + [(ymax—ymin)/(1 + ([inhibitor]/IC50)c] to the data, where y is PfCRT-
mediated CQ transport, ymin and ymax are the minimum and maximum values of y, and c is a
fitted constant. PfCRT-mediated CQ transport was calculated by subtracting the uptake mea-
sured in the control oocytes (oocytes expressing 76K PfCRTK1) from that in oocytes expressing
76I-PfCRTK1 or 76I,369F-PfCRTK1.
A subset of experiments measured the ability of unlabeled amantadine to trans-stimulate the
uptake of [3H]CQ into the oocyte. Immediately prior to the commencement of the experiment,
the oocytes (days 3–4 post-injection of the cRNA) were microinjected with either amantadine
(estimated intracellular concentrations of 1, 2.5, 5, 10, 15, or 20 mM) or a control treatment
(buffer, spermine, or histidine; the estimated intracellular concentrations of spermine and histi-
dine were 5 and 10 mM). The volume injected was 50 nL and the intracellular concentrations
were calculated using previous estimates of the volume of stage V-VI oocytes (~400 nL [77]).
The resealed oocytes were then incubated at 16–18°C in OR2+ buffer for approximately 5 min
and the influx of [3H]CQ was measured as described above. For each amantadine concentration,
the rate of CQ influx above that measured in the relevant buffer-injected control was calculated
and a least-squares fit of the Hill equation (y = Vmax[amantadine]i
n/(Km
n + [amantadine]i
n) to
the data was performed in SigmaPlot, where y is the reaction velocity and n is the Hill coeffi-
cient. This analysis yielded Hill coefficients of 1.63 ± 0.12, 1.49 ± 0.07, and 1.46 ± 0.05 for
PfCRTK1, 76I-PfCRTK1 and 76I,369F-PfCRTK1, respectively. These values indicated that CQ
and amantadine either bind independently of one another, or are slightly cooperative (i.e., the
binding of one drug enhances the affinity of the transporter for the second drug). The Michae-
lis-Menten equation was then fitted to the data to derive the kinetic parameters for the trans-
stimulation of [3H]CQ transport by amantadine.
In most cases, at least five independent experiments were performed (on different days and
using oocytes from different frogs), and within each experiment measurements were made
from 10 oocytes per treatment.
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Culture of P. falciparum-infected erythrocytes
The use of human blood in this study was approved by the Australian National University’s
Human Research Ethics Committee. The CQ-sensitive strain ‘3D7’ (isolated from the Nether-
lands but probably of African origin [78]), the CQ-resistant strain ‘Dd2’ (isolated from South-
east Asia), and three pfcrt transfectant lines [2] (C2GC03, C4Dd2, and C67G8) were cultured and
synchronized as described previously [79, 80]. In the C4Dd2 and C67G8 lines, the wild-type pfcrt
allele of the CQ-sensitive ‘GC03’ strain has been replaced with the pfcrt allele from Dd2 or
from the CQ-resistant ‘7G8’ strain (isolated from Brazil), respectively. C2GC03 is a CQ-sensitive
recombinant control that retains the wild-type pfcrt allele (i.e., PfCRT3D7). C67G8 contains an
additional mutation (I351M) in PfCRT that is not present in 7G8 parasites [36]. The parasite
lines were maintained in the presence of the selection agents blasticidin (5 μM; Sigma-Aldrich)
andWR99210 (5 nM; Jacobus Pharmaceuticals). These selection agents were not present dur-
ing the experiments.
P. falciparum H+ efflux assay
Saponin-isolated trophozoite-stage parasites containing the membrane-impermeant pH-sensi-
tive fluorescent indicator fluorescein-dextran (10,000 MW; Life Technologies) in their DVs
were prepared as outlined elsewhere [36]. The isolated parasites were washed and suspended in
a saline solution (125 mMNaCl, 5 mM KCl, 1 mMMgCl2, 20 mM glucose, 25 mMHEPES; pH
7.1) at a density of 1–3 × 107 cells/mL. The fluorometry experiments were performed as
described previously [35]. The pH of the DV was monitored at 37°C using a PerkinElmer Life
Sciences LS50B fluorometer with a dual excitation Fast Filter accessory (excitation 490 and 450
nm; emission 520 nm). The experiments entailed monitoring the alkalinization of the DV
upon addition of the V-type H+-ATPase inhibitor concanamycin A (100 nM; Sigma-Aldrich),
in the presence or absence of the drugs of interest. Half-times for DV alkalinization (t1/2) were
calculated as outlined elsewhere [34]. In all cases, five independent experiments were per-
formed on different days.
P. falciparum drug susceptibility
Parasite proliferation was measured in 96-well plates using a fluorescent DNA-intercalating
dye [81] and a protocol described in detail previously [82]. Briefly, cell suspensions containing
erythrocytes infected with ring-stage parasites (hematocrit and parasitemia of approximately
2% and 1%, respectively) were incubated at 37°C for 72 h. The samples were frozen, thawed,
and then processed by the addition of 100 μL (per well) of SYBR Safe DNA Gel Stain (Molecu-
lar Probes; 0.2 μL/mL) in a lysis buffer (20 mM Tris, 5 mM EDTA, 0.008% w/v saponin, and
0.08% v/v Triton X-100; pH 7.5). The fluorescence emanating from each well was measured
immediately using a Tecan Infinite M1000 PRO microplate reader (excitation 490 nm; emis-
sion 520 nm) and the average fluorescence from wells containing the highest concentration of
the drug was subtracted from the resulting values. The level of parasite proliferation in the
presence of each drug concentration was expressed as a percentage of the proliferation mea-
sured in the absence of the drug for which the IC50 was being determined. The IC50s were
determined in SigmaPlot by a least-squares fit of the equation y = a/ [1 ([drug]/IC50)c] to the
data, where y is the percent parasite proliferation, a is the maximum change in the percent par-
asite proliferation, and c is a fitted constant. In all cases, five independent experiments were
performed (on different days), and within each experiment measurements were averaged from
three replicates.
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Statistics
All errors cited in the text and shown in the figures represent the SEM. Statistical comparisons
were made using one-way ANOVAs in conjunction with Tukey’s multiple comparisons test.
Supporting Information
S1 Fig. Predicted topology of PfCRT showing the mutations present in the PfCRTK1 vari-
ants characterized in this study. PfCRT is predicted to contain 10 α-helical transmembrane
domains (TMDs) and to be orientated in the digestive vacuole (DV) membrane with the N-
and C-termini extending into the parasite cytosol [83]. The positions of the mutated residues
in PfCRTK1 are indicated with black circles. The key CQ resistance-associated mutation
(K76T) is represented as a red square. The purple circles show the locations of the additional
residues that are mutated in the variants of PfCRTK1. The box attached to each polymorphic
residue lists the (non-wild-type) amino acid(s) that occur at that position. The predicted roles
of the TMDs are as follows: 4 and 9 (outlined in dark green) are implicated in the binding and
translocation of substrates, TMDs 3 and 8 (boxed in light green) are thought to assist in the
binding and translocation of the substrate and may also influence the substrate-specificity of
the transporter, TMDs 1, 2, 6, and 7 (boxed in black) may be involved in recognizing and dis-
criminating between substrates, and TMDs 5 and 10 (outlined in mid-green) are thought to
play a role in the formation of homo-dimers [83].
(TIFF)
S2 Fig. Plots of the quinoline transport activities of PfCRT versus the parasite in vitro drug
responses. (A-C) The CQ, quinine, or quinidine transport activity of a given PfCRTK1 isoform
(calculated from the data presented in Fig 2) was plotted against the in vitro resistance index
for the relevant drug and parasite line (listed in Table 1). Where not shown, error bars fall
within the symbols. There was a positive correlation between the in vitro response of a parasite
line to CQ and the CQ transport properties of the corresponding isoform of PfCRTK1 (panel A:
R2 = 0.856). This is consistent with our previous observation of a positive correlation (R2 =
0.858; [42]) in an analysis performed with seven field isoforms of PfCRT, but contrasts with
the work of Roepe and colleagues, who have not detected a relationship between PfCRTCQR-
mediated CQ transport and the parasite’s response to CQ [84, 85]. In panel B, the quinine
transport activities of many of the PfCRTK1 isoforms correlated positively with the in vitro
responses of the parasites to this drug. However, two key exceptions included the data for the
highly QN-hypersensitive lines 106/176I and 106/176I,369F. Likewise, in panel C, a positive corre-
lation between the capacity of a given PfCRTK1 isoform to transport quinidine and the relevant
parasite’s in vitro quinidine resistance index held for all of the parasites bar the QD-sensitive
line 106/176N. Refer to the main text for a discussion of these outlying points. Note also that
other genetic elements, such as the amplification or mutation of the parasite’s multidrug resis-
tance protein 1 (PfMDR1) and the altered expression of other genes, can contribute to the
quinoline resistance phenotype [7, 86–90]. Hence, the CQ resistance index obtained for the
106/176I line, which is higher than what might be expected from the CQ transport activity of
76I-PfCRTK1, may be due to changes in the expression of one or more genes, including pfmdr1
[14, 89]. High-level CQ resistance has been associated with reductions in the pfmdr1 copy
number and a corresponding decrease in the expression of pfmdr1 [91, 92]. In this regard it is
worth noting that the 106/176I line contains a single copy of pfmdr1, whereas the 106/1, 106/
176T, and 106/176N lines possess two copies, and this difference has been confirmed to result in
a lower level of pfmdr1 expression in the 106/176I parasites [14, 89]. Hence, it is likely that the
relatively high level of CQ resistance displayed by 106/176I is the product of the effects of the
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CQ transport activity of 76I-PfCRTK1, the reduced expression of PfMDR1, and perhaps
changes that have occurred elsewhere in the parasite’s transcriptome. Thus, while this study
and our previous work [42] indicate that the quinoline transport activities of a number of
PfCRT variants correlate positively with the in vitro responses of the respective parasites to
these drugs, changes elsewhere in the genome and transcriptome can modulate the level of
quinoline resistance conferred by PfCRTCQR.
(TIF)
S3 Fig. Isoforms of PfCRTK1 exhibit different CQ, quinine, and quinidine transport
kinetics when expressed in oocytes. (A) The uptake of [3H]CQ (0.25 μM) was measured at
pH 6.0 and over an extracellular concentration range of 10 to 1250 μM unlabeled CQ. (B) The
uptake of [3H]quinine (0.25 μM) was measured at pH 5.0 and the extracellular concentration
of unlabeled quinine ranged between 1 and 300 μM (PfCRTK1 and 76N-PfCRTK1) or 0.25 and
12 μM (76I-PfCRTK1). The inset shows a magnified plot of the 76I-PfCRTK1 data. (C) The
uptake of [3H]quinidine (0.25 μM) was measured at pH 5.0 and the extracellular concentra-
tion of unlabeled quinidine ranged between 1 and 500 μM (PfCRTK1 and 76I-PfCRTK1) or 1
and 750 μM (76N-PfCRTK1). In all cases, the rate of PfCRT-mediated drug uptake was calcu-
lated by subtracting the rate measured in oocytes expressing 76K-PfCRTK1 from that mea-
sured in oocytes expressing PfCRTK1, 76N-PfCRTK1, 76I-PfCRTK1, or 76I,369F-PfCRTK1 at
each drug concentration. The Michaelis-Menten equation was fitted to the resulting data
using nonlinear regression. The rates of drug uptake are the mean ± SEM of multiple inde-
pendent experiments (performed using oocytes from different frogs), within which measure-
ments were made from 10 oocytes per treatment. Where not shown, error bars fall within the
symbols. The exact n values, as well as the kinetic parameters derived from these data, are pre-
sented in Table 2.
(TIF)
S4 Fig. Quinine and quinidine transport activities of the 76I and 76N isoforms of
PfCRTDd2 and PfCRTK1.Noninjected oocytes accumulate low levels of quinine and quinidine
via simple diffusion of the neutral species of the drug [29]. This represents the background
level of drug accumulation. The uptake of (A) [3H]quinine and (B) [3H]quinidine was mea-
sured at pH 5.0 and in the presence of 1 μM of the respective unlabeled drug. The concentra-
tion of the [3H]drug was 0.25 μM. The rates of uptake (pmol per oocyte/h) in noninjected
oocytes and oocytes expressing PfCRTDd2 were 0.10 ± 0.01 and 0.44 ± 0.04, respectively, for
quinine and 0.05 ± 0.01 and 0.30 ± 0.07, respectively, for quinidine. In both panels, drug uptake
is expressed relative to that measured in oocytes expressing PfCRTDd2. The rates of quinine
and quinidine uptake mediated by PfCRTK1 were 1.2–1.3 times that measured for PfCRTDd2,
whereas the 76N-PfCRTK1 protein possessed 3.1 times the quinine transport activity, and 3.2
times the quinidine transport activity, of 76N-PfCRTDd2. Moreover, the rate of quinidine trans-
port mediated by 76I-PfCRTK1 was 1.5 times that measured for 76I-PfCRTDd2. The single
exception to this trend was the rate of quinine transport via 76I-PfCRTK1, which was 0.55
times that measured for its PfCRTDd2 counterpart. The data are the mean + SEM of at least
five independent experiments (performed using oocytes from different frogs), within which
measurements were made from 10 oocytes per treatment. The asterisks denote a significant
difference in drug uptake between the noninjected treatment and that measured in oocytes
expressing a variant of PfCRT: P< 0.05; P< 0.01; P< 0.001 (one-way ANOVA).
(TIF)
S5 Fig. Spermine and histidine do not inhibit the accumulation of [3H]CQ in oocytes
expressing PfCRT. The uptake of [3H]CQ (0.25 μM) was measured in the absence (solvent
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control) or presence of the test compounds (extracellular concentrations of 1 and 2 mM). The
assays were conducted at pH 5.5 and in the presence of 15 μM unlabeled CQ. The rates of CQ
uptake (pmol per oocyte/h) in noninjected oocytes and PfCRTDd2-expressing oocytes were
1.41 ± 0.02 and 24 ± 1.3, respectively. The data are the mean + SEM of four independent exper-
iments performed using oocytes from different frogs), within which measurements were made
from 10 oocytes per treatment. ‘ns’ denotes no significant difference from the PfCRTDd2 con-
trol (P> 0.05; one-way ANOVA).
(TIF)
S6 Fig. Amantadine trans-stimulates the uptake of [3H]CQ into oocytes expressing PfCRT
in a concentration-dependent manner. Control oocytes (noninjected oocytes and oocytes
expressing PfNT1) and oocytes expressing a variant of PfCRT (PfCRT3D7, 76K-PfCRTK1,
PfCRTK1, 76I-PfCRTK1, or 76I,369F-PfCRTK1) were microinjected with buffer containing
amantadine to achieve an estimated intracellular concentration ([amantadine]i) of 1 to 20 mM.
A control was also performed in which the oocytes were microinjected with buffer alone. The
rates of CQ uptake are the mean ± SEM of five independent experiments (performed using
oocytes from different frogs), within which measurements were made from 10 oocytes per
treatment. Where not shown, error bars fall within the symbols. The data presented in Fig 3E
and 3F were calculated by subtracting the rate of CQ uptake measured in the buffer-injected
control from that measured in each of the corresponding amantadine treatments (and within
the same oocyte type). The noninjected data overlays the data obtained with oocytes expressing
PfNT1, PfCRT3D7, or 76K-PfCRTK1.
(TIF)
S7 Fig. Mechanisms for the CQ and quinidine susceptibilities conferred by PfCRT iso-
forms in the malaria parasite. (A) The variants of PfCRTK1 that contain 72R, 76K, 163R,
352K, or 352R (R/K) do not possess significant CQ transport activity. The drug would there-
fore remain in the DV where it exerts an anti-hemozoin effect that kills the parasite, which is
consistent with the CQ-sensitive (S) status of the respective lines. By contrast, PfCRTK1 (76T)
and 76I-PfCRTK1 transport CQ out of the parasite’s DV, thereby conferring CQ resistance
(R). The addition of 369F to 76I-PfCRTK1 significantly reduces its affinity and capacity for
CQ transport. Hence, 76I,369F-PfCRTK1 imparts a relatively low level of resistance (low-R) to
CQ. (B) The R/K variants of PfCRTK1 do not possess significant quinidine (QD) transport
activity whereas PfCRTK1, 76N-PfCRTK1 and 76I-PfCRTK1 each have the ability to transport
QD out of the DV, albeit to varying degrees. These differences in QD transport activity
explain, at least in part, the susceptibilities of the corresponding 106/1 parasite strains to QD.
76N-PfCRTK1 has a slightly lower affinity for QD then does PfCRTK1, and also has a much
lower maximum rate of QD transport. The low capacity and low affinity of QD transport via
76N-PfCRTK1 explains why this protein has little net effect on the parasite’s sensitivity to QD.
By contrast, the relatively high capacity of PfCRTK1 for QD transport is consistent with the
decreased susceptibility of 106/176T parasites to QD (low-R). 76I-PfCRTK1 has a low maxi-
mum rate of QD transport, but this characteristic is counterbalanced by a 3-fold increase in its
affinity for QD, and the net capacity of the protein for QD transport appears to be sufficient
to reduce the parasite’s susceptibility to QD (at least under the conditions of the in vitro para-
site proliferation assays).
(TIF)
S1 Table. Primer sequences used to introduce mutations into the PfCRT coding sequence
via site-directed mutagenesis.
(DOCX)
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